PetVivo Holdings

PetVivo Holdings, Inc. is a veterinary biotech and biomedical device company. It is engaged in the business of translating or adapting human biotech and medical technology into products for commercialization in the veterinary market to treat companion animals such as dogs, horses, cats, and other animals suffering from osteoarthritis and other afflictions. The firm's lead product includes Kush, is an intra-articular injection comprised of patented, gel-like biomaterials that is being commercialized for companion animal osteoarthritis. The company was founded by John Lai and John F. Dolan on March 31, 2009 and is headquartered in Minneapolis, MN.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

PetVivo Holdings reports strong Q1 earnings, eyes market expansion

PetVivo Holdings demonstrated robust financial and operational progress in Q1 2025, driven by strong revenue growth and efficient cost management.
The company's focus on expanding market reach, accelerating Spryng adoption, and enhancing sales and marketing teams positions it for future growth.
While challenges like narrowing net loss persist, PetVivo's strategic initiatives and favorable financial position offer opportunities for sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PetVivo Holdings, Inc. is a veterinary biotech and biomedical device company, which engages in the business of licensing and commercializing medical devices and biomaterials for the treatment and management of afflictions and diseases in animals, initially for dogs and horses. The firm's lead product includes Spryng with OsteoCushion Technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses. The company was founded by John Lai and John F. Dolan on March 31, 2009 and is headquartered in Edina, MN.

PetVivo Holdings, Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.

PetVivo Holdings to Present at Emerging Growth Conference on September 29, 2021

MINNEAPOLIS, MN, US, Sept. 08, 2021 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets is pleased to announce that Josh Wilhelm has accepted a position with the Company as its new Director of Manufacturing.

Josh Wilhelm Joins PetVivo Holdings, Inc. as the Director of Manufacturing

NexGen Energy

Seanergy Maritime Hlds

Verastem

These Reddit penny stocks popped off today, are they worth watching in 2021 The post These Reddit Penny Stocks Exploded Today, Are They On Your List? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

These Reddit Penny Stocks Exploded Today, Are They On Your List?

MINNEAPOLIS, MN, US, Aug. 30, 2021 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets announced today it will be exhibiting at the Western Veterinary Conference to be held September 6th to September 9th, 2021 at the Mandalay Bay Convention Center in Las Vegas, Nevada.

PetVivo Holdings, Inc. to Exhibit at Western Veterinary Conference in Las Vegas, Nevada

MINNEAPOLIS, MN, US, Aug. 23, 2021 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets is pleased to announce that the Company has changed the brand name of its therapeutic osteoarthritis and lameness product to “SPRYNG”.

PetVivo Changes Brand Name of Signature Osteoarthritis Product to “SPRYNG”

MINNEAPOLIS, MN, US, Aug. 19, 2021 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets is pleased to announce that Russell Siakel has accepted a position with the Company as its new Director of Marketing. Mr. Siakel has been guiding the Company's marketing efforts as a consultant since January, 2021.

Russell Siakel Joins PetVivo Holdings, Inc. as the Director of Marketing

PetVivo Holdings to Present at Emerging Growth Conference on August 18, 2021

MINNEAPOLIS, MN, Aug. 13, 2021 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV, PETVW) (“PetVivo” or the “Company”), an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices and therapeutics for pets, today closed its previously announced underwritten public offering of 2,500,000 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock. Each unit was sold to the public at a price of $4.50. The gross proceeds to the Company from the offering were approximately $11.25 million before deducting underwriting discounts, commissions and other offering expenses. The warrants will have a per share exercise price of $5.625, are exercisable immediately, and expire five years from the date of issuance.

PetVivo Holdings Announces Closing of Public Offering and Nasdaq Listing

MINNEAPOLIS, MN, Aug. 10, 2021 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV, PETVW) (“PetVivo” or the “Company”), an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices and therapeutics for pets, today announced the pricing of an underwritten public offering of 2,500,000 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock. Each unit is being sold to the public at a price of $4.50. The gross proceeds to the Company from the offering are expected to be approximately $11.25 million before deducting underwriting discounts, commissions and other offering expenses. The warrants will have a per share exercise price of $5.625, are exercisable immediately, and expire five years from the date of issuance. The common stock and warrants that are part of the units can only be purchased together in the offering but will be issued separately.

PetVivo Holdings Announces Pricing of Public Offering and Nasdaq Listing

MINNEAPOLIS, MN, April 28, 2021 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV) an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices and therapeutics for pets is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a patent related to the Company's proprietary encapsulated or coated stent systems. The broad scope of the issued claims in this patent, entitled “Encapsulated or Coated Stent Systems” provides protection for a broad range of proprietary products, including stents coated with PetVivo's biocompatible coacervate biomaterial.

PetVivo Awarded Key Biocompatible Stent Patent by the United States Patent and Trademark Office

MINNEAPOLIS, MN, US, April 16, 2021 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets is pleased to announce that Robert J. Folkes has accepted a position with the Company as its new Chief Financial Officer.

Robert J. Folkes Joins PetVivo Holdings, Inc. as Chief Financial Officer

News for PetVivo Holdings Stock (PETV)